Treatment of Diabetic Macular Edema With Aflibercept and Micropulse Laser

Diabetic Macular Edema Clinical Trial

— DAM  

Official title:

Treatment of Diabetic Macular Edema With Aflibercept and Micropulse Laser

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03143192
• Other study ID #: 19228
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: March 8, 2017
• Est. completion date: May 9, 2019

Study information

• Verified date: September 2019
• Source: Toronto Retina Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this pilot study is to investigate the safety and efficacy of micropulse (MP) macular laser in combination with intravitreal aflibercept for the treatment of centre-involved diabetic macular edema.

Description:

Diabetic macular edema (DME) is one of the major causes of visual decline among diabetic patients. Early Treatment of Diabetic Retinopathy Study has established focal/grid macular laser as the standard of treatment for clinically significant macular edema. More recently, intravitreal injections of anti-VEGF agents, either as monotherapy or in combination with focal/grid laser, have proven to be superior for the treatment of DME compared to laser alone.

Micropulse (MP) macular laser involves applying the laser in a fraction of the time within very small pockets of energy. Unline traditional focal/grid macular laser, the micropulse method of delivery does not leave any visible burns on the retina.

A recent release by the Diabetic Retinopathy Clinical Research Network has shown that deferring focal/grid laser and treating diabetic macular edema with only anti-VEGF may lead to better visual outcomes. Since MP laser does not have the undesired side effect of leaving laser scars on the macula, the study is to show that prompt MP laser in addition to anti-vegf injections may lead to better visual outcomes and/or decreased treatment burden without the undesired side effect of macular scarring.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 31
• Est. completion date: May 9, 2019
• Est. primary completion date: May 9, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Type I or Type II Diabetes Mellitus

• Presence of centre-involved Diabetic Macular Edema (DME) with the Central Macular Thickness (CMT) of = 310µm on the spectral-domain Optical Coherence Tomography (OCT)

• Best corrected Visual Acuity (BCVA) between, and including, 20/30 and 20/400 in the study eye.

• Patient's willingness and ability to attend the study visits

Exclusion Criteria:

• Any other potential causes of macular edema such as active uveitis, epiretinal membrane, post-operative CME, and vitromacular traction

• Any history of major intraocular surgery (such as cataract surgery or vitrectomy) in the study eye within prior six months, or anticipated need for intraocular surgery within the next six months from the enrollment

• Any major ocular pathology limiting potential vision such as large macular scars, vitreous hemorrhage, corneal opacities, visually significant cataracts, advanced glaucoma, or other types of optic neuropathy

• Any history of Panretinal Photocoagulation (PRP) in the study eye or anticipated need for PRP within the next 6 months from enrollment

• Any history of DME treatment (focal laser, anti-VEGF, or intraocular/periocular steroids) in the study eye in the past 4 months prior to the enrollment

• Significant renal disease requiring dialysis

• Significant heart disease, stroke or transient ischemic attack requiring hospitalization in the past 4 months prior to the study

• Presence of active ocular or periocular infection

• Presence of active intraocular inflammation

• Known hypersensitivity to aflibercept or to any ingredient in the formulation or to any component of the container

Related Conditions & MeSH terms

• Diabetic Macular Edema
• Edema
• Macular Edema

Intervention

Combination Product:
• Micropulse Laser
Aflibercept injection with Micropulse laser.

Device:
• Sham Laser
Aflibercept injection with Sham Laser

Locations

Country	Name	City	State
Canada	Mississauga Retina Institute	Mississauga	Ontario
Canada	Toronto Retina Institute	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Keyvan Koushan

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of injections for each group	Number of intravitreal injections for each group	48 weeks
Secondary	Changes in visual acuity	Changes in visual acuity from baseline to 24 adjusted for baseline	24 weeks
Secondary	Changes in visual acuity	Changes in visual acuity from baseline to 48 weeks adjusted for baseline	48 weeks
Secondary	Changes in OCT Central Macular Thickness and Volume	Measurement changes in central macular thickness at 24 weeks	24 weeks
Secondary	Changes in OCT Central Macular Thickness and Volume	Measurement changes in central macular thickness at 48 weeks	48 weeks
Secondary	Number of injections half way	Number of intravitreal injections of each group at 24 weeks	24 weeks
Secondary	Proportion of eyes with 2 or 3 lines of visual gain or loss	Improvement or deterioration of vision of 2 or 3 lines at 24 weeks	24 weeks
Secondary	Proportion of eyes with 2 or 3 lines of visual gain or loss	Improvement or deterioration of vision of 2 or 3 lines at 48 weeks	48 weeks
Secondary	Proportion of eyes that achieve 20/20 vision	Eyes that are able to see 20/20 at 24 weeks regardless of baseline	24 weeks
Secondary	Proportion of eyes that achieve 20/20 vision	Eyes that are able to see 20/20 at 48 weeks regardless of baseline	48 weeks
Secondary	Proportion of eyes that have PRP, vitreous hemorrhage, and vitrectomy.	Proportion of eyes in each study group that require panretinal photocoagulation, have a vitreous hemorrhage, or require a vitrectomy during the course of the study.	48 weeks
Secondary	Proportion of eyes that had vision or OCT improvement	In patients with HbA1c = 8% or separately measured in patients with HbA1C > 8%	48 weeks